Cargando…
Neurocognitive function among HIV-infected children on protease inhibitor -based versus non-protease inhibitor based antiretroviral therapy in Uganda: a pilot study
BACKGROUND: HIV infection is associated with significant neurocognitive deficits making maximization of cognitive function among children receiving antiretroviral therapy (ART) a public health imperative. Non-protease inhibitors (non-PIs) achieve higher drug levels in the cerebral spinal fluid (CSF)...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8073947/ https://www.ncbi.nlm.nih.gov/pubmed/33902506 http://dx.doi.org/10.1186/s12887-021-02676-2 |
_version_ | 1783684246243639296 |
---|---|
author | Nalwanga, Damalie Musiime, Victor Bangirana, Paul Nishiguchi, Erika Phelps Kiggwe, Andrew Ssesanga, Titus Ssenkusu, John M. Musoke, Philippa Cusick, Sarah E. |
author_facet | Nalwanga, Damalie Musiime, Victor Bangirana, Paul Nishiguchi, Erika Phelps Kiggwe, Andrew Ssesanga, Titus Ssenkusu, John M. Musoke, Philippa Cusick, Sarah E. |
author_sort | Nalwanga, Damalie |
collection | PubMed |
description | BACKGROUND: HIV infection is associated with significant neurocognitive deficits making maximization of cognitive function among children receiving antiretroviral therapy (ART) a public health imperative. Non-protease inhibitors (non-PIs) achieve higher drug levels in the cerebral spinal fluid (CSF) compared to PIs, potentially leading to better neurocognitive function by reducing CSF viral load and inflammation. ART that maximises children’s neurodevelopment and school achievement could result in improved quality of life and productivity as adults, but little research to date has examined whether non-PI ART is associated with better neurocognitive outcomes. We compared the neurocognitive function between children living with HIV receiving PI-based and non PI-based ART. METHODS: We recruited a consecutive sample of clinically stable Ugandan children living with HIV aged 5–12 years who received PI-based or non PI-based ART for ≥ 1 year (viral load < 1000 copies). Neurocognitive function was assessed using the Kaufman Assessment Battery for Children, the Test of Variables of Attention, and Bruininks-Oseretsky Test of Motor Proficiency. Age-adjusted neurocognitive z-scores for the two groups were compared using linear regression models in STATA version 13. The Hommel’s method was used to adjust for multiple testing. RESULTS: We enrolled 76 children living with HIV; 34 on PI ART and 42 on non-PI ART. Mean (±SD) age was greater in the non-PI vs. PI group (9.5 ± 1.9 vs. 8.5 ± 2.0) years (p = 0.03). Children in the non-PI group had lower socioeconomic scores (5.7 ± 3.3 vs. 7.4 ± 2.8, p = 0.02). There was no difference in neurocognitive function between the groups (adjusted p > 0.05) for KABC and TOVA. Children in the PI group had better total BOT scores than their counterparts (46.07 ± 1.40) vs. 40.51 (1.24), p = 0.03). CONCLUSIONS: We detected no difference in neurocognitive function among children on PI and non PI-based ART therapy based on KABC and TOVA tests. Children on PI based ART had better motor function than their counterparts. We recommend a prospective study with a larger sample size. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12887-021-02676-2. |
format | Online Article Text |
id | pubmed-8073947 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-80739472021-04-26 Neurocognitive function among HIV-infected children on protease inhibitor -based versus non-protease inhibitor based antiretroviral therapy in Uganda: a pilot study Nalwanga, Damalie Musiime, Victor Bangirana, Paul Nishiguchi, Erika Phelps Kiggwe, Andrew Ssesanga, Titus Ssenkusu, John M. Musoke, Philippa Cusick, Sarah E. BMC Pediatr Research Article BACKGROUND: HIV infection is associated with significant neurocognitive deficits making maximization of cognitive function among children receiving antiretroviral therapy (ART) a public health imperative. Non-protease inhibitors (non-PIs) achieve higher drug levels in the cerebral spinal fluid (CSF) compared to PIs, potentially leading to better neurocognitive function by reducing CSF viral load and inflammation. ART that maximises children’s neurodevelopment and school achievement could result in improved quality of life and productivity as adults, but little research to date has examined whether non-PI ART is associated with better neurocognitive outcomes. We compared the neurocognitive function between children living with HIV receiving PI-based and non PI-based ART. METHODS: We recruited a consecutive sample of clinically stable Ugandan children living with HIV aged 5–12 years who received PI-based or non PI-based ART for ≥ 1 year (viral load < 1000 copies). Neurocognitive function was assessed using the Kaufman Assessment Battery for Children, the Test of Variables of Attention, and Bruininks-Oseretsky Test of Motor Proficiency. Age-adjusted neurocognitive z-scores for the two groups were compared using linear regression models in STATA version 13. The Hommel’s method was used to adjust for multiple testing. RESULTS: We enrolled 76 children living with HIV; 34 on PI ART and 42 on non-PI ART. Mean (±SD) age was greater in the non-PI vs. PI group (9.5 ± 1.9 vs. 8.5 ± 2.0) years (p = 0.03). Children in the non-PI group had lower socioeconomic scores (5.7 ± 3.3 vs. 7.4 ± 2.8, p = 0.02). There was no difference in neurocognitive function between the groups (adjusted p > 0.05) for KABC and TOVA. Children in the PI group had better total BOT scores than their counterparts (46.07 ± 1.40) vs. 40.51 (1.24), p = 0.03). CONCLUSIONS: We detected no difference in neurocognitive function among children on PI and non PI-based ART therapy based on KABC and TOVA tests. Children on PI based ART had better motor function than their counterparts. We recommend a prospective study with a larger sample size. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12887-021-02676-2. BioMed Central 2021-04-26 /pmc/articles/PMC8073947/ /pubmed/33902506 http://dx.doi.org/10.1186/s12887-021-02676-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Nalwanga, Damalie Musiime, Victor Bangirana, Paul Nishiguchi, Erika Phelps Kiggwe, Andrew Ssesanga, Titus Ssenkusu, John M. Musoke, Philippa Cusick, Sarah E. Neurocognitive function among HIV-infected children on protease inhibitor -based versus non-protease inhibitor based antiretroviral therapy in Uganda: a pilot study |
title | Neurocognitive function among HIV-infected children on protease inhibitor -based versus non-protease inhibitor based antiretroviral therapy in Uganda: a pilot study |
title_full | Neurocognitive function among HIV-infected children on protease inhibitor -based versus non-protease inhibitor based antiretroviral therapy in Uganda: a pilot study |
title_fullStr | Neurocognitive function among HIV-infected children on protease inhibitor -based versus non-protease inhibitor based antiretroviral therapy in Uganda: a pilot study |
title_full_unstemmed | Neurocognitive function among HIV-infected children on protease inhibitor -based versus non-protease inhibitor based antiretroviral therapy in Uganda: a pilot study |
title_short | Neurocognitive function among HIV-infected children on protease inhibitor -based versus non-protease inhibitor based antiretroviral therapy in Uganda: a pilot study |
title_sort | neurocognitive function among hiv-infected children on protease inhibitor -based versus non-protease inhibitor based antiretroviral therapy in uganda: a pilot study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8073947/ https://www.ncbi.nlm.nih.gov/pubmed/33902506 http://dx.doi.org/10.1186/s12887-021-02676-2 |
work_keys_str_mv | AT nalwangadamalie neurocognitivefunctionamonghivinfectedchildrenonproteaseinhibitorbasedversusnonproteaseinhibitorbasedantiretroviraltherapyinugandaapilotstudy AT musiimevictor neurocognitivefunctionamonghivinfectedchildrenonproteaseinhibitorbasedversusnonproteaseinhibitorbasedantiretroviraltherapyinugandaapilotstudy AT bangiranapaul neurocognitivefunctionamonghivinfectedchildrenonproteaseinhibitorbasedversusnonproteaseinhibitorbasedantiretroviraltherapyinugandaapilotstudy AT nishiguchierikaphelps neurocognitivefunctionamonghivinfectedchildrenonproteaseinhibitorbasedversusnonproteaseinhibitorbasedantiretroviraltherapyinugandaapilotstudy AT kiggweandrew neurocognitivefunctionamonghivinfectedchildrenonproteaseinhibitorbasedversusnonproteaseinhibitorbasedantiretroviraltherapyinugandaapilotstudy AT ssesangatitus neurocognitivefunctionamonghivinfectedchildrenonproteaseinhibitorbasedversusnonproteaseinhibitorbasedantiretroviraltherapyinugandaapilotstudy AT ssenkusujohnm neurocognitivefunctionamonghivinfectedchildrenonproteaseinhibitorbasedversusnonproteaseinhibitorbasedantiretroviraltherapyinugandaapilotstudy AT musokephilippa neurocognitivefunctionamonghivinfectedchildrenonproteaseinhibitorbasedversusnonproteaseinhibitorbasedantiretroviraltherapyinugandaapilotstudy AT cusicksarahe neurocognitivefunctionamonghivinfectedchildrenonproteaseinhibitorbasedversusnonproteaseinhibitorbasedantiretroviraltherapyinugandaapilotstudy |